Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E28.23 EPS (ttm)1.74 Insider Own0.10% Shs Outstand1.66B Perf Week0.84%
Market Cap81.40B Forward P/E29.08 EPS next Y1.69 Insider Trans19.46% Shs Float1.65B Perf Month3.54%
Income2.89B PEG1.95 EPS next Q0.44 Inst Own71.80% Short Float1.84% Perf Quarter-2.94%
Sales16.37B P/S4.97 EPS this Y32.80% Inst Trans-0.01% Short Ratio3.57 Perf Half Y-8.72%
Book/sh9.37 P/B5.24 EPS next Y-4.85% ROA8.00% Target Price52.62 Perf Year12.33%
Cash/sh4.26 P/C11.53 EPS next 5Y14.50% ROE19.40% 52W Range39.95 - 56.66 Perf YTD-6.24%
Dividend1.44 P/FCF47.44 EPS past 5Y-3.60% ROI10.70% 52W High-13.33% Beta0.42
Dividend %2.93% Quick Ratio1.60 Sales past 5Y-1.50% Gross Margin72.40% 52W Low22.94% ATR0.71
Employees28000 Current Ratio1.90 Sales Q/Q-0.50% Oper. Margin20.40% RSI (14)57.28 Volatility1.31% 1.44%
OptionableYes Debt/Eq0.49 EPS Q/Q51.40% Profit Margin17.70% Rel Volume0.58 Prev Close49.12
ShortableYes LT Debt/Eq0.48 EarningsJul 24 BMO Payout80.10% Avg Volume8.52M Price49.11
Recom2.40 SMA201.13% SMA501.61% SMA200-2.39% Volume1,991,316 Change-0.02%
15-Jan-14Reiterated Argus Buy $58 → $62
10-Jan-14Upgrade Barclays Equal Weight → Overweight $52 → $65
20-Dec-13Reiterated UBS Neutral $48 → $54
29-Jul-13Reiterated Argus Buy $54
17-Jul-13Reiterated Barclays Equal Weight $42 → $45
04-Jun-13Reiterated Argus Buy $46 → $54
26-Apr-13Reiterated MKM Partners Sell $26 → $29
15-Apr-13Reiterated Barclays Equal Weight $33 → $42
25-Jan-13Reiterated UBS Neutral $34 → $36
09-Jan-12Reiterated Barclays Capital Overweight $34 → $36
19-Oct-11Initiated MKM Partners Sell $26
27-Jun-11Reiterated UBS Neutral $28 → $30
31-Mar-11Downgrade Jefferies Buy → Hold $28.50
28-Mar-11Reiterated Barclays Capital Overweight $28 → $30
22-Sep-10Reiterated Deutsche Bank Buy $28 → $31.50
01-Sep-10Reiterated UBS Neutral $26 → $27
31-Aug-10Upgrade Jefferies Hold → Buy $28.80 → $30
12-Mar-10Initiated Jefferies & Co Hold $27
16-Dec-09Initiated UBS Neutral
09-Oct-09Initiated Wells Fargo Outperform
22-Jul-14 02:44PM  3 Stocks Reiterated As A Buy: EBAY, BMY, EMC at TheStreet
06:13AM  [$$] 9 Health Care Stocks From Index-Crushing Fund at Barrons.com
21-Jul-14 12:00AM  Perrigo, Actelion Tax Targets Abroad for U.S. Drugmakers at Bloomberg
18-Jul-14 03:45PM  Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis Zacks
02:37PM  What You Need to Know About Johnson & Johnson's Best-Selling Drugs at Motley Fool
17-Jul-14 08:06AM  Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion Business Wire
16-Jul-14 02:02PM  Keep Calm and Carry On, J&J at Motley Fool
06:21AM  Cramer's Lightning Round - General Electric Needs To Bring Good Things To Life (7/15/14) at Seeking Alpha
15-Jul-14 11:13AM  Perrigo retreats after analyst sees limited potential buyers at theflyonthewall.com
14-Jul-14 05:01PM  1 Hidden Blockbuster Lurking in Merck's Pipeline? at Motley Fool
11:27AM  Is Bristol-Myers Squibb Overvalued? at Seeking Alpha
10:40AM  Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co? at Motley Fool
13-Jul-14 03:32PM  This Week in Biotech: Anacor's FDA A-OK and AbbVie's Insatiable Urge to Buy Something at Motley Fool
11-Jul-14 05:01PM  1 Drug More Important to Gilead Than Sovaldi at Motley Fool
04:30PM  Bristol-Myers to Seek U.S. Approval for Immuno-Oncology Drug Zacks
11:35AM  Senators Ask Gilead To Explain Sovaldi Pricing at Investor's Business Daily
08:52AM  How Gilead Sciences Can Deliver A Double: Part Two at Forbes
10-Jul-14 06:45PM  Bristol seeks cancer drug nod Investor's Business Daily
01:07PM  Bristol-Myers Squibb Selects GEP To Provide Strategic Category Management And Related Procurement Services In Long-Term Program PR Newswire
12:43PM  Bristol-Myers announces plans for Q3 submission of Opdivo BLA at theflyonthewall.com
12:36PM  Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma Business Wire
10:24AM  Bristol-Myers Seeking Nivolumab Approval In Melanoma at Investor's Business Daily
09:22AM  Bristol to seek melanoma approval for Opdivo ahead of expectations Reuters
08:56AM  Top Biotech Stocks to Watch Today: Allergan, Arena Pharmaceuticals and Bristol-Myers Squibb at Motley Fool
07:30AM  Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma Business Wire
09-Jul-14 03:53PM  Credit Suisse names vice chairman of healthcare group -memo Reuters
03:13AM  If AbbVie Wants Shires Low Tax Rate, Price May Go Up Bloomberg
08-Jul-14 12:29PM  3 Stocks Reiterated As A Buy: BMY, CAT, CELG at TheStreet
10:40AM  Bristol-Myers Gains Japanese Approval for HCV Combo Drug Zacks
07:20AM  Bristol-Myers price target lowered to $55 from $62 at Leerink at theflyonthewall.com
07-Jul-14 06:58PM  Japan approves BMY regimen Investor's Business Daily
06:28PM  Cramer's Bristol-Myers theorem: What is it? at CNBC
06:18PM  Jazz, Novo Among Medicals Showing Healthy Action at Investor's Business Daily
06:00PM  Cramer's 'Mad Money' Recap: Timing Is Everything at TheStreet
02:35PM  [$$] Novartis Leukemia Treatment Gets 'Breakthrough' Status at The Wall Street Journal
02:02PM  Is Bristol-Myers Squibb Co. Destined for Greatness? at Motley Fool
12:23PM  Bristol-Myers' All-Oral HCV Therapy Approved In Japan at Investor's Business Daily
09:12AM  Make Your Move TheStreet
09:04AM  Mondays Top Biotech Stories: Spectrum, Bristol-Myers Squibb, GSK, and Theravance at Motley Fool
07:41AM  Bristol-Myers hepatitis C drug gets approval in Japan Reuters
07:39AM  [$$] Japan Approves Bristol-Myers Squibb's Hepatitis C Treatment at The Wall Street Journal
07:00AM  Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen Business Wire
03-Jul-14 04:51PM  Bristol-Myers Squibb May Be Fast-Tracking Its Promising Cancer Drug at Seeking Alpha
09:18AM  New Stock Coverage: Parsley Energy a Sage Investment Over Time? at Minyanville
02-Jul-14 11:34AM  No Perfect Prescription: Barclays Cuts Bristol-Myers, Upgrades AbbVie at Barrons.com
10:06AM  UPDATE: Barclays Downgrades Bristol-Myers, Cuts Price Target By 41% Benzinga
09:47AM  [video] The Top Ten Stocks for Wednesday, July 2 at Bloomberg
01-Jul-14 12:34PM  Bristol-Myers recalls six lots of blood thinner injection Reuters
12:09PM  Isis - Addressing Some Of The Bull Arguments To My Short Thesis at Seeking Alpha
10:11AM  Bristol-Myers Squibb to Announce Results for Second Quarter on July 24 Business Wire
10:08AM  Is AstraZeneca's Dividend Safe? at Motley Fool
30-Jun-14 01:02PM  Why Are Companion Diagnostics So Important? at Motley Fool
11:10AM  CHMP Positive on Bristol-Myers/Pfizer's Eliquis for New Indication Zacks
27-Jun-14 11:27AM  Bristol-Myers Squibb: Expect Accelerated Dividend Growth In The Near Term at Seeking Alpha
11:27AM  Bristol-Myers Squibb: Expect Accelerated Dividend Growth In The Near Term
10:07AM  Ex-Dividend Reminder: Bristol-Myers Squibb, Medtronic and Mack Cali Realty
09:36AM  Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments Benzinga
09:36AM  Pfizer, Bristol-Myers Squibb Announce Positive Opinion For Treatments
07:58AM  [$$] Bristol-Myers Gets Positive CHMP Opinions at The Wall Street Journal
07:58AM  [$$] Bristol-Myers Gets Positive CHMP Opinions
07:11AM  Bristol-Myers gets positive Hep C opinion from EMA committee at MarketWatch
07:11AM  Bristol-Myers gets positive Hep C opinion from EMA committee
07:01AM  Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment of Chronic Hepatitis C in the European Union Benzinga
07:01AM  Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza for Treatment of Chronic Hepatitis C in the European Union
07:01AM  Pfizer, Bristol clot drug wins EU green light for wider use Reuters
07:01AM  Pfizer, Bristol clot drug wins EU green light for wider use
07:00AM  Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE Business Wire
07:00AM  Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
07:00AM  Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union Business Wire
07:00AM  Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
26-Jun-14 09:45AM  Bristol-Myers Up on Nivolumab News Zacks
09:45AM  Bristol-Myers Up on Nivolumab News
25-Jun-14 12:21PM  Why Bristol-Myers Squibb (BMY) Stock Is Climbing Today at TheStreet
12:21PM  Why Bristol-Myers Squibb (BMY) Stock Is Climbing Today
11:28AM  Midday movers: CBS, HBI, MON, BMY, MDCI & More
11:11AM  Bristol-Myers Stock Up On Nivolumab Trial Success
09:07AM  Morning Movers: Monsanto, Pioneer
09:02AM  General Mills earnings miss; Apollo beats estimates; Aerie shares soar
08:53AM  Robo-advisors, Syrian strikes and the stock-market shift they signal
07:55AM  U.S. economy shrank 2.9% in Q1 GDP; U.S. loosens ban on oil exports; Google I/O developer conference
07:55AM  BREAKING: Revised Q1 GDP; U.S. loosens ban on oil exports; Google I/O developer conference
07:42AM  Bristol-Myers shares set for a meaningful run, says Credit Suisse
07:39AM  US STOCKS-Futures flat after decline, GDP data awaited
24-Jun-14 07:53PM  On The Fly: After Hours Movers
06:32PM  Bristol-Myers says cancer drug met goal in study
06:11PM  Bristol-Myers Stops Skin Cancer Study on Positive Data
05:58PM  [$$] Bristol-Myers's Melanoma Treatment Compares Favorably
05:27PM  Bristol immunotherapy prolongs survival in melanoma trial
05:16PM  Bristol-Myers shares rise on melanoma drug study
04:47PM  Bristol-Myers says Phase 3 study of nivolumab versus dacarbazine stopped early
04:45PM  Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
02:56PM  US slaps duties on steel pipes from Malaysia, Vietnam, Thailand
09:20AM  Bristol-Myers Is Almost In The 'Buy Zone'
09:07AM  Will This Price Target Decrease Hurt Bristol-Myers Squibb (BMY) Stock Today?
08:00AM  Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute
01:20AM  Bristol-Myers Squibb's Oncology Opportunity
23-Jun-14 04:44PM  This chart spells trouble for Pfizer
04:44PM  Pfizer can use some Viagra: Analysts
04:29PM  3 Stocks Reiterated As A Buy: MDLZ, BMY, BIIB
09:37AM  Shire Says Holders Deserve Higher as AbbVie Eyes Offer
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DANIELS BRIANSVP Global Dev & Med AffairsJul 01Option Exercise0.004,671096,477Jul 02 06:35 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 05Option Exercise0.0013,9900662,469May 06 09:17 PM
Elicker John ESVP Pub Affairs & Inv RelationMay 03Option Exercise0.001,509050,536May 05 05:05 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000042,595May 02 04:18 PM
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM
Caforio GiovanniEVP & Chief Commercial OfficerJan 03Option Exercise0.007,500054,817Jan 06 05:40 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660201,827Nov 04 04:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,869Oct 04 04:19 PM
Heller Frances KSVP, Business DevelopmentOct 01Option Exercise0.004,45104,451Oct 02 04:23 PM
CORNELIUS JAMES MDirectorJul 29Option Exercise25.615,000128,025647,383Jul 29 04:44 PM
CORNELIUS JAMES MDirectorJul 29Sale43.92100,0004,392,000542,383Jul 30 04:34 PM
CORNELIUS JAMES MDirectorJul 29Sale43.815,000219,050642,383Jul 29 04:44 PM